Alaunos Therapeutics (NASDAQ:TCRT) Announces Earnings Results

Posted by Jeff Wilder on May 17th, 2026

Alaunos Therapeutics (NASDAQ:TCRT – Get Free Report) issued its quarterly earnings data on Friday. The company reported ($0.59) EPS for the quarter, FiscalAI reports.

Alaunos Therapeutics Trading Down 2.0%

NASDAQ TCRT opened at $2.47 on Friday. The firm’s fifty day simple moving average is $2.93 and its two-hundred day simple moving average is $3.05. Alaunos Therapeutics has a 12-month low of $1.67 and a 12-month high of $6.20. The firm has a market capitalization of $5.93 million, a P/E ratio of -1.16 and a beta of -1.13.

Hedge Funds Weigh In On Alaunos Therapeutics

An institutional investor recently bought a new position in Alaunos Therapeutics stock. HRT Financial LP purchased a new position in Alaunos Therapeutics, Inc. (NASDAQ:TCRT – Free Report) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 12,602 shares of the company’s stock, valued at approximately $40,000. HRT Financial LP owned about 0.54% of Alaunos Therapeutics at the end of the most recent quarter. Institutional investors and hedge funds own 27.72% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Weiss Ratings raised shares of Alaunos Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company currently has a consensus rating of “Sell”.

Check Out Our Latest Report on Alaunos Therapeutics

Alaunos Therapeutics Company Profile

(Get Free Report)

Alaunos Therapeutics, Inc, a clinical-stage oncology-focused cell therapy company, develops adoptive T-cell receptor (TCR) engineered T-cell therapies (TCR-T) to treat multiple solid tumor types. It develops Library TCR-T Cell Theraphy, which is in Phase I/II clinical trial for 12 TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers. The company is also developing hunTR, a human neoantigen TCR discovery engine; and Sleeping Beauty Gene Transfer Platform, a non-viral genetic engineering technology.